Boehringer Ingelheim

This study tests an experimental drug called BI 764524, given as an eye injection, in 190 adults with moderate to severe diabetic retinopathy. Participants receive different numbers of injections over a year, and doctors compare eye damage improvements against a sham procedure or…

This study tests whether survodutide, a weekly injection for weight loss, is safe for the heart in people who are overweight or obese and have heart or kidney disease. About 5,500 adults will receive either survodutide or a placebo for up to 2 years, along with diet and exercise …

This study tests whether combining three different antibodies—BI 770371, pembrolizumab, and cetuximab—can shrink tumors in people with head and neck cancer that has spread or come back. About 91 adults are randomly assigned to one of three treatment groups. The goal is to see if …

This early-phase trial tests a new drug called BI 764532 (Obrixtamig) given together with standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC), a rare and fast-growing cancer. The study involves about 55 adults whose tumors have a specific marker (DLL3). …

This early-stage trial tests an experimental drug called BI 3000202 in 16 adults with rare type 1 interferonopathies, such as Aicardi-Goutières syndrome. Participants take a low dose for 4 weeks, then a higher dose for 36 weeks. The main goal is to see if the drug is safe and how…

This Phase 3 trial tests whether the oral drug zongertinib can slow cancer growth better than standard chemotherapy plus immunotherapy in people with advanced HER2-mutant non-small cell lung cancer. About 428 adults who have not had prior treatment for advanced disease will be ra…

This study tests a new immunotherapy for adults with advanced pancreatic cancer. The treatment uses a special protein and virus to help the immune system kill cancer cells, combined with an antibody called ezabenlimab. The goal is to find a safe dose and see if the combination ca…

This study tests a mix of antibodies that help the immune system fight cancer, block tumor growth signals, and cut off the tumor's blood supply. It is for adults with head and neck cancer that did not respond to prior treatment or has no standard options. Participants receive inf…

This early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …

This study tests whether a new drug called vicadrostat, combined with the existing drug empagliflozin, can help people with chronic kidney disease (CKD) that is getting worse. About 492 adults with CKD will be randomly assigned to start both drugs together or one after the other …

This early-stage trial tests a new antibody-like drug called BI 764532 alongside standard chemotherapy in adults with advanced small cell lung cancer that has returned after platinum-based treatment. The main goal is to find a safe dose and check for side effects. About 69 partic…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This study is testing whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. Adults with GPP who have had a flare will receive a single intravenous dose of spesolimab, with a possible second …

This study looks at how well the diabetes drug empagliflozin (Jardiance) works in everyday medical practice, outside of a controlled research setting. Researchers are comparing it to other diabetes medicines in over 230,000 adults with type 2 diabetes. The goal is to see if the h…

This early-stage trial tests a new daily pill, zongertinib, in adults with advanced cancers that have HER2 gene changes, including non-small cell lung cancer. The first part finds the safest dose; the second checks if it shrinks tumors. Participants stay on the drug as long as it…

This study tests a daily tablet called BI 1291583 (Verducatib) in 268 adults with bronchiectasis, a long-term lung condition. Participants who were in earlier trials continue or switch to the drug for up to one year. The main goal is to check safety and see if the drug reduces lu…

This early-stage trial tests a new drug called BI 764532 in 20 adults with a type of brain tumor (glioma) that has a specific marker called DLL3 and hasn't improved with prior treatment. The drug is designed to link cancer cells to immune cells, helping the body fight the tumor. …

This early-phase trial tests a new drug called BI 764532 (obrixtamig) added to standard chemotherapy and immunotherapy for people with extensive-stage small cell lung cancer. The main goal is to find the highest safe dose of BI 764532 when given with standard treatments. About 46…

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This early-phase trial tests a new drug called BI 765179, an antibody that helps the immune system fight cancer. It is given alone or with other drugs (ezabenlimab or pembrolizumab) to adults with advanced solid tumors or head and neck cancer. The study aims to find the best dose…

This study tests a new medicine called BI 771716 for geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 202 adults aged 50 and older will receive either the new drug or an existing treatment (pegcetacoplan) as eye injections. T…

This study tests whether survodutide, a new weekly injection, helps people with obesity burn more energy and fat compared to the existing drug semaglutide (Wegovy). 64 adults aged 18-65 with a BMI between 30 and 45 will be randomly assigned to one of the two drugs. Researchers wi…

This early-stage trial tests two drugs, obrixtamig and ezabenlimab, given together as infusions to adults with advanced small cell lung cancer or other neuroendocrine tumors that have a specific marker called DLL3. The main goal is to find the highest safe dose of obrixtamig when…

This study looks at the long-term safety and effectiveness of spesolimab in people with generalized pustular psoriasis (GPP), a rare and severe skin condition. All 131 participants had already taken spesolimab in a previous study and will continue treatment for up to 5 years. Res…

This study was designed to track the safety and effectiveness of spesolimab (Spevigo®) in Korean adults experiencing flares of generalized pustular psoriasis (GPP), a severe skin condition. The study was withdrawn before enrolling any participants, so no data were collected. It w…

This study is tracking over 1,000 Japanese patients with chronic kidney disease who are taking JARDIANCE® (empagliflozin) daily for a long period. Researchers are monitoring side effects and whether the drug helps slow kidney decline in real-world conditions. The goal is to see i…

This study tests a drug called BI 1584862 in 150 adults aged 50+ with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. Participants receive either the drug or a placebo for 1 year. Doctors track changes in the retina using special …

This early-phase study tests a new drug, BI 1823911, alone or with another drug (BI 1701963), in people with advanced solid tumors that have a KRAS G12C mutation. The goal is to find a safe dose and see if the drugs can shrink tumors. About 30 adults with cancers like lung, color…

This early-stage study tests a new drug called BI 1701963, which blocks a cancer-driving protein called KRAS. It is given alone or with an approved drug, trametinib, to adults with advanced solid tumors that have a KRAS mutation and have not responded to prior chemotherapy. The m…

This study follows 2,000 people with systemic sclerosis (scleroderma) who have lung disease and are taking the drug nintedanib (Ofev®). Researchers want to see how the drug affects lung function, quality of life, and survival over the long term. The study is observational, meanin…

This early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…

This early-stage trial tests whether a daily tablet called BI 1356225 can improve impulse control in people with opioid use disorder who are already taking buprenorphine. About 60 participants will be randomly assigned to receive either the study drug or a placebo for 8 days. Res…

This study tests a smartphone app called CT-155 designed to help people with schizophrenia manage negative symptoms like low motivation and reduced pleasure. About 262 adults with schizophrenia will use the app for 16 weeks, with an optional extension. Researchers will track symp…

This early-stage study tests the safety and how the body handles multiple doses of an experimental drug called verducatib in 12 healthy Chinese adults aged 18 to 55. Participants take the drug by mouth for 4 weeks. The goal is to gather information to support future development o…

This study monitors the long-term safety of the drug Ofev in people with lung disease caused by scleroderma. Researchers are tracking side effects like diarrhea and nausea in 586 patients in Japan who are starting Ofev for the first time. The goal is to see how common these side …

This study is for adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments. Researchers use special PET scans to see how two experimental drugs (BI 765063 and BI 770371) travel through the body and reach tumors. Participants receive one …

This study looks at whether SGLT2 inhibitors, a type of diabetes drug, can help prevent or manage anemia in people with chronic kidney disease. Researchers will analyze data from 15,000 patients in Japan to see how these drugs affect anemia rates, treatments, and costs. The goal …

This study follows 5 people with cystic fibrosis who previously received a single dose of BI 3720931 gene therapy or placebo. No new treatment is given. Researchers will monitor participants for up to 15 years to check for long-term side effects and track lung function. The goal …

This study tests a new formulation of survodutide, a medicine being developed for obesity and liver conditions. About 100 healthy adults aged 18-65 with a BMI between 27 and 40 will receive weekly injections of either the current or new formula for 28 weeks. Researchers will meas…

This study looks at real-world treatment patterns and outcomes for nearly 8,000 people with HER2-altered metastatic breast cancer in the United States. Researchers will analyze data from medical records to understand how patients are treated and how long they live. The goal is to…

This study is collecting blood samples from 102 patients with non-small cell lung cancer, colorectal cancer, or pancreatic cancer who are receiving standard treatments. Researchers will analyze the blood for cancer DNA (ctDNA) to see how it changes over time and whether it relate…

This study follows 157 adults with pulmonary fibrosis who are taking nintedanib and enrolled in a patient support program in Spain. Researchers will measure how satisfied patients are with the program, their quality of life, and any depression symptoms over 12 months. The goal is…

This study analyzes health records from over 547,000 people in France who started taking SGLT2 inhibitors for type 2 diabetes between 2020 and 2024. Researchers will describe patient characteristics, prescription patterns, and track the occurrence of heart attacks, strokes, heart…